Shanghai Rongsheng Biotech Co.,Ltd.

Shanghai Rongsheng Biotech Co., Ltd. (hereinafter referred to as Rongsheng Bio or he Company), established in 1988, is a state-level high-tech enterprise specializing in the research and development, production, and sales of vaccines and diagnostic reagents. The Company has always adhered to the mission of being a responsible player in the biopharmaceutical industry for human health and has actively participated in the research of major national science and technology projects and the formulation of five industry standards. Over the past 36 years, through independent innovation and research, the Company has continuously optimized and improved its scientific research capabilities and industrial production capacity. Its third-generation Weikobang varicella attenuated live vaccine, which does not contain gelatin or human blood albumin, has gained market recognition. Since its launch, it has been used in 31 provinces, autonomous regions, and municipalities across China. The Company has also established a diversified pipeline of research projects and an array of innovative and upgraded products, with several products being among the top in China in terms of development and clinical progress.